Amphastar Pharmaceuticals (AMPH) Assets Average (2014 - 2026)

Amphastar Pharmaceuticals' Assets Average history runs 13 years deep, the most recent figure standing at $1.6 billion for Q1 2026.

• In Q1 2026, Assets Average rose 2.3% year-over-year to $1.6 billion; the TTM figure through Mar 2026 stood at $1.6 billion (up 2.3% YoY), while the FY2025 annual figure was $1.6 billion, up 3.77% from the prior year.
• Assets Average was $1.6 billion for Q1 2026 at Amphastar Pharmaceuticals, down from $1.6 billion in the prior quarter.
• In the past five years, Assets Average ranged from a high of $1.6 billion in Q4 2025 to a low of $693.9 million in Q1 2022.
• Historically, Assets Average has averaged $1.3 billion across 5 years, with a median of $1.5 billion in 2023.
• The sharpest annual moves came in 2023 and 2024: Assets Average surged 108.18% in 2023, then climbed 2.13% in 2024.
• A 5-year view of Assets Average shows it stood at $734.3 million in 2022, then soared by 108.18% to $1.5 billion in 2023, then increased by 2.13% to $1.6 billion in 2024, then climbed by 5.54% to $1.6 billion in 2025, then slipped by 0.55% to $1.6 billion in 2026.
• The last three Assets Average figures came in at $1.6 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.6 billion (Q3 2025), per Business Quant data.